Human retinal endothelial cells express functional interleukin-6 receptor

被引:0
作者
Lisia Barros Ferreira
Liam M. Ashander
Binoy Appukuttan
Yuefang Ma
Keryn A. Williams
Giles Best
Justine R. Smith
机构
[1] Flinders University College of Medicine and Public Health,
[2] Flinders Medical Centre,undefined
来源
Journal of Ophthalmic Inflammation and Infection | / 13卷
关键词
Uveitis; Retina; Endothelial cell; Human; Interleukin-6; Receptor;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 86 条
[1]  
Tode J(2017)Intravitreal injection of anti-Interleukin (IL)-6 antibody attenuates experimental autoimmune uveitis in mice Cytokine 96 8-15
[2]  
Richert E(2016)The cytokine interleukin-6 and the chemokines CCL20 and CXCL13 are novel biomarkers of specific endogenous uveitic entities Invest Ophthalmol Vis Sci 57 4606-4613
[3]  
Koinzer S(2020)Cytokine profiling in aqueous humor samples from patients with non-infectious uveitis associated with systemic inflammatory diseases Front Immunol 11 358-470
[4]  
Abu El-Asrar AM(2011)Understanding uveitis: the impact of research on visual outcomes Prog Retin Eye Res 30 452-94
[5]  
Berghmans N(2019)Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients Am J Ophthalmol 200 85-529
[6]  
Al-Obeidan SA(2022)Anti-tumor necrosis factor alpha versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French Uveitis Network Ophthalmology 129 520-888
[7]  
Bonacini M(2011)The pro- and anti-inflammatory properties of the cytokine interleukin-6 Biochim Biophys Acta. 1813 878-348
[8]  
Soriano A(2022)IL-6 revisited: from rheumatoid arthritis to CAR T cell therapy and COVID-19 Annu Rev Immunol 40 323-2684
[9]  
Cimino L(2022)Transcriptomic responses of human retinal vascular endothelial cells to inflammatory cytokines Transl Vis Sci Technol 11 27-229
[10]  
de Smet MD(2007)Unique gene expression profiles of donor-matched human retinal and choroidal vascular endothelial cells Invest Ophthalmol Vis Sci 48 2676-180